WallStreetZenWallStreetZen

NASDAQ: AXNX
Axonics Inc Stock Forecast, Predictions & Price Target

Analyst price target for AXNX

Based on 5 analysts offering 12 month price targets for Axonics Inc.
Min Forecast
$71.00+5.65%
Avg Forecast
$71.00+5.65%
Max Forecast
$71.00+5.65%

Should I buy or sell AXNX stock?

Based on 5 analysts offering ratings for Axonics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
5 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AXNX stock forecasts and price targets.

AXNX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-29
lockedlocked$00.00+00.00%2024-01-16
lockedlocked$00.00+00.00%2024-01-12
lockedlocked$00.00+00.00%2024-01-12
lockedlocked$00.00+00.00%2024-01-10

1 of 1

Forecast return on equity

Is AXNX forecast to generate an efficient return?
Company
14.56%
Industry
27.42%
Market
82.5%
AXNX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AXNX forecast to generate an efficient return on assets?
Company
12.76%
Industry
14.15%
AXNX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AXNX earnings per share forecast

What is AXNX's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$0.13
Avg 2 year Forecast
$0.66
Avg 3 year Forecast
$1.14

AXNX revenue forecast

What is AXNX's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$448.2M+15.77%
Avg 2 year Forecast
$538.5M+39.11%
Avg 3 year Forecast
$628.0M+62.22%
AXNX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AXNX revenue growth forecast

How is AXNX forecast to perform vs Medical Devices companies and vs the US market?
Company
17.51%
Industry
8.09%
Market
9.95%
AXNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AXNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AXNX vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
AXNX$67.20$71.00+5.65%Hold
PRCT$63.17$67.25+6.46%Strong Buy
ITGR$116.31$133.00+14.35%Strong Buy
IRTC$94.33$131.50+39.40%Strong Buy
TNDM$45.33$51.36+13.31%Strong Buy

Axonics Stock Forecast FAQ

Is Axonics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: AXNX) stock is to Hold AXNX stock.

Out of 5 analysts, 0 (0%) are recommending AXNX as a Strong Buy, 0 (0%) are recommending AXNX as a Buy, 5 (100%) are recommending AXNX as a Hold, 0 (0%) are recommending AXNX as a Sell, and 0 (0%) are recommending AXNX as a Strong Sell.

If you're new to stock investing, here's how to buy Axonics stock.

What is AXNX's earnings growth forecast for 2024-2026?

(NASDAQ: AXNX) Axonics's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 23.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.82%.

Axonics's earnings in 2024 is -$15,952,000.On average, 7 Wall Street analysts forecast AXNX's earnings for 2024 to be $6,413,023, with the lowest AXNX earnings forecast at -$22,448,130, and the highest AXNX earnings forecast at $27,549,978. On average, 6 Wall Street analysts forecast AXNX's earnings for 2025 to be $33,840,556, with the lowest AXNX earnings forecast at $19,387,022, and the highest AXNX earnings forecast at $45,916,630.

In 2026, AXNX is forecast to generate $57,992,704 in earnings, with the lowest earnings forecast at $48,467,554 and the highest earnings forecast at $65,813,837.

What is AXNX's revenue growth forecast for 2024-2026?

(NASDAQ: AXNX) Axonics's forecast annual revenue growth rate of 17.51% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.09%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.

Axonics's revenue in 2024 is $387,138,000.On average, 5 Wall Street analysts forecast AXNX's revenue for 2024 to be $22,865,461,470, with the lowest AXNX revenue forecast at $22,611,389,450, and the highest AXNX revenue forecast at $23,366,462,924. On average, 5 Wall Street analysts forecast AXNX's revenue for 2025 to be $27,474,929,939, with the lowest AXNX revenue forecast at $26,708,173,233, and the highest AXNX revenue forecast at $28,315,255,290.

In 2026, AXNX is forecast to generate $32,041,287,794 in revenue, with the lowest revenue forecast at $31,271,316,924 and the highest revenue forecast at $32,731,414,746.

What is AXNX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: AXNX) forecast ROA is 12.76%, which is lower than the forecast US Medical Devices industry average of 14.15%.

What is AXNX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year AXNX price target, the average AXNX price target is $71.00, with the highest AXNX stock price forecast at $71.00 and the lowest AXNX stock price forecast at $71.00.

On average, Wall Street analysts predict that Axonics's share price could reach $71.00 by Feb 28, 2025. The average Axonics stock price prediction forecasts a potential upside of 5.65% from the current AXNX share price of $67.20.

What is AXNX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: AXNX) Axonics's current Earnings Per Share (EPS) is -$0.31. On average, analysts forecast that AXNX's EPS will be $0.13 for 2024, with the lowest EPS forecast at -$0.44, and the highest EPS forecast at $0.54. On average, analysts forecast that AXNX's EPS will be $0.66 for 2025, with the lowest EPS forecast at $0.38, and the highest EPS forecast at $0.90. In 2026, AXNX's EPS is forecast to hit $1.14 (min: $0.95, max: $1.29).

What is AXNX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: AXNX) forecast ROE is 14.56%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.